BioNexus Gene Lab Corp. Proceeds from Sale of Equity Method Investments
BioNexus Gene Lab Corp. (BGLC) reported Proceeds from Sale of Equity Method Investments of $1.03 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfEquityMethodInvestments · last filed 2026-04-14
- BioNexus Gene Lab Corp. proceeds from sale of equity method investments for the quarter ending 2025-12-31 was $10.76K, a 98.13% decline year-over-year.
- BioNexus Gene Lab Corp. proceeds from sale of equity method investments for the quarter ending 2024-12-31 was $574.04K.
- BioNexus Gene Lab Corp. proceeds from sale of equity method investments for the quarter ending 2024-09-30 was $197.06K.
- BioNexus Gene Lab Corp. proceeds from sale of equity method investments for fiscal 2025 was $1.03M, a 3.48% decline from fiscal 2024.
- BioNexus Gene Lab Corp. proceeds from sale of equity method investments for fiscal 2024 was $1.07M.
| Period end | Proceeds from Sale of Equity Method Investments 3 month | Proceeds from Sale of Equity Method Investments 6 month | Proceeds from Sale of Equity Method Investments 9 month | Proceeds from Sale of Equity Method Investments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $10.76K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $1.03M 10-K · filed 2026-04-14 | ||
| 2025-09-30 | $1.02M 10-Q · filed 2025-11-14 | |||
| 2024-12-31 | $574.04K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $771.10K derived: sum of 2 quarters · filed 2026-04-14 | $1.07M 10-K · filed 2026-04-14 | |
| 2024-09-30 | $197.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $494.74K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $297.68K 10-Q · filed 2025-08-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |